Aclasta is used to treat osteoporosis in postmenopausal women and men with low bone density. It strengthens bones and increases their hardness, reducing the risk of fractures. It is also used to treat Paget's disease, which causes bone deformities and weakening over time. It helps regulate bone formation and breakdown in a balanced manner.
It is given as an intravenous injection once a year, making patients more committed to treatment.
Aclasta works to stabilize calcium within the bones and enhance their long-term strength. It also reduces complications associated with osteoporosis, such as back pain or difficulty moving, improving the patient's quality of life and increasing their ability to perform daily activities.